var data={"title":"Doxercalciferol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Doxercalciferol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6074?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=doxercalciferol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Doxercalciferol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163084\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hectorol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163085\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Hectorol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163101\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vitamin D Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163088\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Secondary hyperparathyroidism: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dialysis patients: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial dose: iPTH &gt;400 pg/mL: 10 mcg 3 times/week at dialysis for 8 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dose titration: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level &gt;300 pg/mL (dose should be titrated to lower iPTH to within the range of 150 to 300 pg/mL): Increase to 12.5 mcg 3 times/week at dialysis for 8 more weeks; this titration process can continue at 8-week intervals in 2.5 mcg/dose increments (maximum: 20 mcg 3 times/week).  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level 150 to 300 pg/mL: Maintain current dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level &lt;100 pg/mL: Suspend doxercalciferol for 1 week; resume at a reduced dose; decrease each dose (not weekly dose) by at least 2.5 mcg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hypercalcemia, hyperphosphatemia, or serum calcium times serum phosphorus product &gt;55 mg<sup>2</sup>/dL<sup>2</sup>: Decrease or suspend dose and/or adjust dose of phosphate binders; if dose is suspended, resume at a reduced dose; decrease each dose (not weekly dose) by at least 2.5 mcg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Predialysis patients:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial dose: iPTH &gt;70 pg/mL with stage 3 disease or &gt;110 pg/mL with stage 4 disease: 1 mcg/day for 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dose titration: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level &gt;70 pg/mL with stage 3 disease or &gt;110 pg/mL with stage 4 disease (dose should be titrated to lower iPTH to 35 to 70 pg/mL with stage 3 disease or to 70 to 110 pg/mL with stage 4 disease): Increase dose by 0.5 mcg per day every 2 weeks as necessary (maximum dose: 3.5 mcg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level 35 to 70 pg/mL with stage 3 disease or 70 to 110 pg/mL with stage 4 disease: Maintain current dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level is &lt;35 pg/mL with stage 3 disease or &lt;70 pg/mL with stage 4 disease: Suspend doxercalciferol for 1 week, then resume at a reduced dose (at least 0.5 mcg per day lower) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hypercalcemia, hyperphosphatemia, or serum calcium times serum phosphorus product &gt;55 mg<sup>2</sup>/dL<sup>2</sup>: Decrease or suspend dose and/or adjust dose of phosphate binders; if dose is suspended, resume at a reduced dose (at least 0.5 mcg per day lower).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>IV:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dialysis patients: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Initial dose: iPTH level &gt;400 pg/mL: 4 mcg 3 times/week at the end of dialysis; adjust as needed to lower iPTH into a range of 150 to 300 pg/mL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dose titration (increase dose at 8-week intervals):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level decreased by &lt;50% and &gt;300 pg/mL (dose should be titrated to lower iPTH to within a range of 150 to 300 pg/mL): Increase by 1 to 2 mcg at 8-week intervals, as necessary  (doses &gt;18 mcg/week have not been studied). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level decreased by &gt;50% and &gt;300 pg/mL: Maintain current dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level 150 to 300 pg/mL: Maintain current dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">iPTH level &lt;100 pg/mL: Suspend doxercalciferol for 1 week; resume at a reduced dose (at least 1 mcg lower)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hypercalcemia, hyperphosphatemia, or serum calcium times serum phosphorus product &gt;55 mg<sup>2</sup>/dL<sup>2</sup>: Decrease or suspend dose and/or adjust dose of phosphate binders; if dose is suspended, resume at a reduced dose (at least 1 mcg lower)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163089\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163090\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. The major metabolite, 1&alpha;,25-(OH)<sub>2</sub>D<sub>2</sub>, is not removed by hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163091\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution and consider more frequent monitoring of iPTH, calcium, and phosphorus levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163067\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hectorol: 0.5 mcg [DSC] [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hectorol: 1 mcg [DSC] [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hectorol: 2.5 mcg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mcg, 1 mcg, 2.5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hectorol: 2 mcg/mL (1 mL); 4 mcg/2 mL (2 mL) [contains alcohol, usp, disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mcg/2 mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163052\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25343362\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Injection: Administer as an IV bolus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163069\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism (dialysis):</b> Injection, oral: Treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Secondary hyperparathyroidism (predialysis patients):</b> Oral: Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163059\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse events as reported in dialysis patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (28%), malaise (28%), dizziness (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Bradycardia (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Sleep disorder (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (5%), hyperphosphatemia (2% to 4%), hypercalcemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (5%), dyspepsia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (including anaphylaxis, angioedema, hypotension, unresponsive to stimuli, chest discomfort, dyspnea, pruritus, burning sensation of skin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163072\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to doxercalciferol or any component of the formulation; tendency toward hypercalcemia or evidence of vitamin D toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163056\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypercalcemia: Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures; chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification, including the heart and arteries. Phosphate and vitamin D (and its derivatives) should be withheld during therapy to avoid hypercalcemia. Avoid use in patients with a recent history of hypercalcemia. Patients with high calcium levels (&gt;10.5 mg/dL) prior to treatment are more likely to develop hypercalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Serious hypersensitivity reactions (some fatal), including anaphylaxis with angioedema, dyspnea, hypotension, chest discomfort, cardiopulmonary arrest, and unresponsiveness, have been reported with IV doxercalciferol. Monitor for hypersensitivity when initiating IV treatment; discontinue if such reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Patients with hepatic insufficiency may not appropriately metabolize doxercalciferol. Use with caution in patients with hepatic impairment; may require more frequent iPTH, calcium, and phosphorous monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperphosphatemia: Avoid use in patients with a recent history of hyperphosphatemia. Patients with high phosphorous levels (&gt;6.9 mg/dL) prior to treatment are more likely to develop hyperphosphatemia. Correct before initiating therapy; exacerbates secondary hyperparathyroidism, diminishing the effect of doxercalciferol. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Doxercalciferol is not for initial treatment of nutritional vitamin D deficiency. Other forms of vitamin D should be discontinued when doxercalciferol is started. Do not administer doxercalciferol to patients with a recent history of hypercalcemia or hyperphosphatemia, or evidence of vitamin D toxicity (may have increased risk of hypercalcemia or hyperphosphatemia).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299232\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163061\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8651&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase serum concentrations of the active metabolite(s) of Doxercalciferol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Doxercalciferol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Doxercalciferol may enhance the hypermagnesemic effect of Magnesium Salts.  Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163063\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163075\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163076\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if doxercalciferol is excreted in breast milk. Other vitamin D derivatives are excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163077\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Based on serum levels, dietary phosphorus may be restricted and/or controlled with phosphorus binders. The daily combined calcium intake (dietary and calcium based phosphate binder) should be 1.5 to 2 g. Additional vitamin D supplements and magnesium-containing antacids should be avoided. Capsules contain coconut oil.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163065\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CKD stage 3: Every 6 to 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CKD stage 4: Every 3 to 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CKD stage 5 and 5D: Every 1 to 3 months </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">In dialysis patients, iPTH, serum calcium and phosphorus should be determined prior to initiation of therapy and weekly thereafter for the first 12 weeks. For predialysis patients, serum calcium and phosphorus and plasma levels of iPTH should be monitored at least every two weeks for 3 months after initiation of therapy or following dose adjustments, then monthly for 3 months, and every 3 months thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3 to 12 months depending on CKD severity; signs/symptoms of hypersensitivity reactions (upon IV initiation)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163068\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4 to 10.2 mg/dL (2.1 to 2.6 mmol/L); CKD stage 5: 8.4 to 9.5 mg/dL (2.1 to 2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus (K/DOQI, 2003): CKD stages 3 and 4: 2.7 to 4.6 mg/dL (0.87 to 1.48 mmol/L); CKD stage 5 (including those treated with dialysis): 3.5 to 5.5 mg/dL (1.13 to 1.78 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg<sup>2</sup>/dL<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0 to 5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0 to 65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0 to 6.0 pmol/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Target ranges by stage of chronic kidney disease (KDIGO 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2 to 9 times the upper limit of normal for the assay used</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163055\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Doxercalciferol is metabolized to the active form of vitamin D. The active form of vitamin D controls the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidneys, and in conjunction with PTH, the mobilization of calcium from the skeleton.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163071\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP27 to active metabolites, 1&alpha;,25-(OH)<sub>2</sub>D<sub>2</sub> (major) and 1&alpha;,24-dihydroxyvitamin D<sub>2</sub> (minor).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Major metabolite: ~32 to 37 hours (range: up to 96 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Major metabolite: 2.1 to 13.9 hours (injection); 11 to 12 hours (oral).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163074\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Doxercalciferol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mcg (50): $784.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mcg (50): $1,567.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mcg (50): $1,816.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Doxercalciferol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg/2 mL (2 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hectorol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mcg/mL (1 mL): $7.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg/2 mL (2 mL): $15.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163078\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Hectorol (CA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Eknoyan G, Levin A, and Levin NW, &ldquo;Bone Metabolism and Disease in Chronic Kidney Disease,&rdquo; <i>Am J Kidney Dis</i>, 2003, 42(4 Suppl 3):1-201.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hectorol (doxercalciferol injection) [prescribing information]. Cambridge, MA: Genzyme; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hectorol capsules (doxercalciferol injection) [prescribing information]. Cambridge, MA: Genzyme; February 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 3. Evaluation of Serum Phosphorus Levels.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at  http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm14520607</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8A. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD.&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide8A.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8B. Vitamin D Therapy in Patients on Dialysis (CKD Stage 5).&quot; Available at http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide8B.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, &quot;KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),&quot; <i>Kidney Int Suppl</i>, 2009, 76(S113):1-130.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/doxercalciferol-drug-information/abstract-text/19644521/pubmed\" target=\"_blank\" id=\"19644521\">19644521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, &quot;KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease,&quot;<i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8651 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F163084\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F163085\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F163101\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F163088\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F163089\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F163090\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F163091\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F163067\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F163052\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F25343362\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F163069\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F163059\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F163072\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F163056\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299232\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F163061\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F163063\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F163075\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F163076\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F163077\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F163065\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F163068\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F163055\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F163071\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F163074\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F163078\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8651|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=doxercalciferol-patient-drug-information\" class=\"drug drug_patient\">Doxercalciferol: Patient drug information</a></li></ul></div></div>","javascript":null}